Trending

COPD

GSK’s Nucala unlikely to get COPD use after panel vote

GSK’s Nucala unlikely to get COPD use after panel vote

FDA due to make decision in September

X

GSK’s Nucala unlikely to get COPD use after panel vote

https://pharmaphorum.com/news/gsks-nucala-unlikely-to-get-copd-use-after-panel-vote/

NICE restricts use of antibiotics in draft COPD guidance

NICE restricts use of antibiotics in draft COPD guidance

NICE has published draft guidance restricting use of antibiotics in patients with chronic obstructive pulmonary disease (COPD), as

X

NICE restricts use of antibiotics in draft COPD guidance

https://pharmaphorum.com/news/nice-restricts-use-of-antibiotics-in-draft-copd-guidance/

AstraZeneca’s respiratory biologic fails again in COPD

AstraZeneca’s respiratory biologic fails again in COPD

AstraZeneca (AZ) and MedImmune, have announced that the latest trial of Fasenra (benralizumab) in patients with moderate-to-very-severe chronic obstructive pulmonary disease (COPD) did not provide a statistically-significant reduction in exacerbations.

X

AstraZeneca’s respiratory biologic fails again in COPD

https://pharmaphorum.com/news/astrazenecas-respiratory-biologic-copd/

Blow for AZ as late stage COPD trial fails

Blow for AZ as late stage COPD trial fails

GSK also hopes to get IL-5 drug approved in COPD

X

Blow for AZ as late stage COPD trial fails

https://pharmaphorum.com/news/blow-for-az-as-late-stage-copd-trial-fails/

Boehringer Ingelheim rolls-out COPD digital adherence programme

Boehringer Ingelheim rolls-out COPD digital adherence programme

Boehringer Ingelheim has expanded access to a digital adherence programme that helps COPD patients take their medicines as

X

Boehringer Ingelheim rolls-out COPD digital adherence programme

https://pharmaphorum.com/news/boehringer-copd-digital-adherence/

FDA approves expanded use for GSK’s COPD triple therapy

FDA approves expanded use for GSK’s COPD triple therapy

GSK is aiming to revive its respiratory drugs franchise

X

FDA approves expanded use for GSK’s COPD triple therapy

https://pharmaphorum.com/news/fda-approves-expanded-use-for-gsks-copd-triple-therapy/

SMi’s Asthma & COPD conference next week in London

SMi’s Asthma & COPD conference next week in London

SMi Group reports: Limited availability on Managers Special Discount Last call [Managers Special offer – £500 savings]

X

SMi’s Asthma & COPD conference next week in London

https://pharmaphorum.com/partner-content/smis-asthma-copd-conference-next-week-in-london/

Verona to take COPD hopeful into phase 3

Verona to take COPD hopeful into phase 3

Verona Pharma is to take lung drug RPL554 into late clinical development after a successful phase 2b trial.

X

Verona to take COPD hopeful into phase 3

https://pharmaphorum.com/market-access-2/verona-to-take-copd-hopeful-into-phase-3/

AZ boosted by COPD triple inhaler results

AZ boosted by COPD triple inhaler results

AstraZeneca may mount a challenge to GlaxoSmithKline’s three-in-one inhaler for chronic obstructive pulmonary disease (COPD) after a late-stage

X

AZ boosted by COPD triple inhaler results

https://pharmaphorum.com/news/az-boosted-copd-triple-inhaler-results/

1 2 3 4 5

CONTINUE TO SITE >

Close in 10 seconds

Pharmaphorum.com